Earn CME: https://www.naccme.com/program/19-cpc-101-6 This webcast features a presentation by Dr. Alexander B. Olawaiye that discusses the integration of PARP inhibitors into evidence-based ovarian cancer clinical pathways based on discrete PARP factors, latest clinical data, and guideline recommendations for the treatment of ovarian cancer. © 2019 NACCME, an HMP Company
Navigating Rapid Change in Ovarian Cancer: PARP Inhibitors in Clinical Pathways
